Suppr超能文献

美国食品药品监督管理局关于人工晶状体的报告。

The FDA report on intraocular lenses.

作者信息

Stark W J, Worthen D M, Holladay J T, Bath P E, Jacobs M E, Murray G C, McGhee E T, Talbott M W, Shipp M D, Thomas N E

出版信息

Aust J Ophthalmol. 1984 Feb;12(1):61-9.

PMID:6547332
Abstract

Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since 9 February 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409 000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45 000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of posterior chamber and anterior chamber IOLs.

摘要

自1978年2月9日起,美国食品药品监督管理局(FDA)对作为研究器械的人工晶状体(IOL)进行临床研究实施监管。截至1982年8月,已收集了超过100万例人工晶状体植入的数据。在研究的最后12个月里,植入了409000例人工晶状体。在超过45000例接受评估的病例中,85%在术后一年视力达到20/40或更好。患者年龄增加、手术问题、术后并发症和不良反应是导致视力下降的因素。美国目前的趋势是植入后房型和前房型人工晶状体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验